Table 4.

Quality of life in breast cancer patients before and after intervention in KD group and control group as measured by the EORTC QLQBR23^a

	KD	Control	p-value
aFunctioning
Future perspective
Week 0	66 (33–100)	66 (33–66)	0/60
Week 12	66 (33–66)	33 (33–100)	0/85
p-value	0/45	0/76
bSymptoms+
Arm
Week 0	11 (0–36)	11 (0–22)	0/36
Week 12	11 (0–36)	22 (0–33)	88
p-value	0/70	0/59
Breast
Week 0	8 (0–33)	8 (0–25)	0/34
Week 12	8 (0–10)	8 (0–16)	0/55
p-value	0/01	0/34
Systemic therapy side effects
Week 0	9 (4–17)	14 (4–23)	0/54
Week 12	42 (20–52)	42 (33–52)	0/33
p-value	0</001	0</001
Concerns over hair loss
Week 0	0	0	0/20
Week 12	66 (33–100)	33 (33–100)	0/50
p-value	0</001	0</001

Mann–Whitney U test was used to compare the continuous variables between the two groups. Wilcoxon was used to compare the continuous variables within the two groups

^aThe higher values indicate higher level of functioning and quality of life

^bThe higher values indicate a higher grade of symptoms

Data shown as median and quartile (25, 75)